USE1

Across TCGA pan-cancer cohorts, USE1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of USE1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where USE1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types USE1 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

KIRC, LIHC, and COAD are the cancer types where USE1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in USE1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.893	<.001	12	view →
LIHC	Male	II,III,IV	+1.016	<.001	9	view →
COAD	Female	All	+0.667	<.001	9	view →
KICH	Female	II,III,IV	−1.074	<.001	7	view →
ESCA	All	II,III,IV	+1.015	.004	4	view →
LUSC	All	All	+0.321	<.001	4	view →
BRCA	Female	II,III,IV	−0.223	.006	4	view →
CHOL	All	All	+0.988	<.001	3	view →
HNSC	Male	IV	+0.498	.010	3	view →
PRAD	All	All	+0.232	.012	2	view →
BLCA	Male	IV	−0.404	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

USE1–KIRC

Open the KIRC breakdown →